Semler Scientific

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Semler Scientific posts record revenue and profit growth in Q4

Semler Scientific delivered robust financial performance in Q4 2022, marked by record revenue, profit growth, and a strong cash position.
The company's strengths lie in its revenue diversification, profitability improvement, and strategic leadership transition.
Challenges include managing operating expenses, sustaining revenue growth across segments, and ensuring a smooth CEO transition.
Opportunities for Semler include expansion, innovation in healthcare technologies, and leveraging market demand for its services for future growth.

Semler Scientific achieves record Q1 earnings amidst strategic growth

Semler Scientific delivered robust financial performance in Q1 2023, marked by record revenue and pre-tax net income, underpinned by strong liquidity.
The company's strategic focus on governance, product innovation, and confidence in product benefits positions it well to navigate challenges and seize growth opportunities.
Despite cost management challenges and regulatory uncertainties, Semler's resilience, financial strength, and commitment to innovation bode well for future success.

Semler Scientific reports record revenue and profit growth in Q2

Semler Scientific's Q2 2023 performance showcased robust revenue growth, driven by successful QuantaFlo sales, and a significant increase in pre-tax net income.
The company's strategic initiatives, including leadership changes, product introductions, and operational streamlining, demonstrate a focus on sustainable growth and innovation.
While facing challenges such as cost management and workforce reduction, Semler Scientific is well-positioned to leverage opportunities in market expansion, technology advancements, and clinical benefits delivery.

Semler Scientific excels in Q3 with strong revenue growth

Semler Scientific's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and growth opportunities. The company's focus on innovation and market expansion positions it well for future success.

Semler Scientific reports solid Q4 earnings, eyes growth in cardiovascular diagnosis

Semler Scientific's Q4 2023 earnings call showcased positive financial performance, strategic growth initiatives, and a commitment to innovation in cardiovascular disease diagnosis.
Despite challenges such as operating expenses and fixed fee revenue decline, the company's adaptability and focus on clinical benefits position it well for future opportunities.
Analyst inquiries and executive responses highlighted a strong emphasis on efficiency improvements, market adaptability, and regulatory clearances for continued growth.

Semler Scientific reports earnings growth, eyes new product clearance

Semler Scientific's Q1 2024 performance showed growth in earnings and effective cost management.
While facing revenue challenges, the company is strategically positioned to capitalize on growth opportunities.
With a focus on innovation and market expansion, Semler aims to drive future revenue growth.
The company's strong financial position and strategic initiatives position it well for future success.

Semler Scientific adopts bitcoin treasury, reports stable Q2 performance

Semler Scientific's Q2 2024 performance reflects a strategic shift towards bitcoin as a treasury asset and a focus on core business operations.
While facing revenue challenges and cost management needs, the company's financial strength and flexibility position it well for future growth.
Opportunities lie in leveraging debt securities for expansion and capitalizing on the potential of bitcoin as a long-term investment.

Semler Scientific reports robust Q3 earnings, diversifies into Bitcoin

Semler Scientific's Q3 2024 performance reflects resilience in income generation and prudent cost control measures.
The company's strategic focus on Bitcoin acquisitions and product innovation positions it for potential growth and market leadership.
While facing revenue challenges and financial risks, Semler's exploration of financing options and regulatory compliance efforts signal a proactive stance.
Opportunities lie in leveraging operational strength for expansion, diversifying investment strategies, and capitalizing on early disease diagnosis capabilities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

SANTA CLARA, Calif. , April 7, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian, and chief marketing officer, Dennis Rosenberg, will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET.

Semler to Participate in the 21st Annual Needham Virtual Healthcare Conference

SANTA CLARA, Calif. , March 14, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its board of directors has authorized a $20.0 million stock repurchase program.

Semler Scientific's Board of Directors authorizes an up to $20.0 million stock repurchase program

A shift in Variable Fee purchasing behavior post-Covid contributed to revenue contraction in Q4.

Semler Scientific: Why I'm Buying

SANTA CLARA, Calif., March 1, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced a study was published on-line as a pre-proof in the peer-reviewed Journal of Vascular Surgery with data collected using QuantaFlo® under real-world conditions.

Clinical Study using QuantaFlo® published in Peer-Reviewed Journal of Vascular Surgery

Semler Scientific, Inc. (SMLR) CEO Douglas Murphy-Chutorian on Q4 2021 Results - Earnings Call Transcript

SANTA CLARA, Calif., Feb. 28, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months and year ended December 31, 2021.

Semler Reports Fourth Quarter and Year-to-Date 2021 Financial Results

Semler operates in a niche market in which it has the only viable alternative to standard tests for peripheral arterial disease.

Semler's Unique Business Model Is Fueling Profitable Growth

SANTA CLARA, Calif., Feb. 17, 2022 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021, after the close of U.S. financial markets on Monday, February 28, 2022.

Semler to Report Fourth Quarter and Year End 2021 Financial Results and Host Conference Call on February 28, 2022

Semler faces near-term risks that don't seem to be factored into consensus expectations.

Better Price For Semler Is Likely

Amerant Bancorp

Costamare

Bancorp

Investors who are seeking opportunities among growth stocks could be interested in the following small-cap stocks, as they represent companies whose trailing 12-month net income per share has improved significantly on a year-over-year basis. Wall Street sell-side analysts have also issued optimistic recommendation ratings for them.

4 Small Caps for Growth-Oriented Investors

The company reported slowing growth, but is there hope?

Is Semler Scientific Stock Still a Buy After Its Earnings Miss?

Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q3 2021 Results - Earnings Call Transcript

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of -21.54% and -10.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Semler Scientific Inc. (SMLR) Q3 Earnings and Revenues Miss Estimates

SANTA CLARA, Calif., Nov. 1, 2021 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and nine months ended September 30, 2021.

Semler Reports Third Quarter and Year-to-Date 2021 Financial Results

SANTA CLARA, Calif., Oct. 22, 2021 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the third quarter and first nine months ended September 30, 2021, after the close of U.S. financial markets on Monday, November 1, 2021.

Semler to Report Third Quarter and First Nine Months of 2021 Financial Results and Host Conference Call on November 1, 2021

Market is not fully pricing in their revenue growth potential. They have a strong balance sheet with high liquidity.

Semler Scientific: Rapidly Growing Medical Device Company

With Semler moving to the Nasdaq, the company's strong business model will be more visible to investors.

This Top Small-Cap Just Became a Better Buy

Semler Scientific Inc. (SMLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Semler Scientific Inc. (SMLR) Surges 11.7%: Is This an Indication of Further Gains?

SANTA CLARA, Calif., Sept. 27, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has approved the listing of its common stock on the exchange.

Semler Scientific to Commence Trading on Nasdaq

Semler Scientific reported their Q2 2021 earnings recently on August 2, 2021. Results were strong across the board and showed strong growth in revenue profitability.

Semler Scientific: A Remarkable Quarter Shows Strong Execution

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 36.07% and -1.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Semler Scientific Inc. (SMLR) Q2 Earnings Top Estimates

Semler Scientific, Inc. (SMLR) CEO Doug Murphy-Chutorian on Q2 2021 Results - Earnings Call Transcript

SANTA CLARA, Calif., Aug. 2, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and six months ended June 30, 2021.

Semler Reports Second Quarter and First Half of 2021 Financial Results

Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Semler Scientific Inc. (SMLR) Reports Next Week: Wall Street Expects Earnings Growth

SANTA CLARA, Calif., July 21, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the second quarter and first half ended June 30, 2021, after the close of U.S. financial markets on Monday, August 2, 2021.

News for Semler Scientific Stock (SMLR)